Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy

BACKGROUND. Several breast cancer (BC) trials have adopted pathological complete response (pCR) as a surrogate marker of long‐term treatment efficacy. In patients with luminal subtype, pCR seems less important for outcome prediction. BC is a heterogeneous disease, which is evident in residual tumors...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Cabrera‐Galeana, Paula, Muñoz‐Montaño, Wendy, Lara‐Medina, Fernando, Alvarado‐Miranda, Alberto, Pérez‐Sánchez, Victor, Villarreal‐Garza, Cynthia, Quintero, R. Marisol, Porras‐Reyes, Fany, Bargallo‐Rocha, Enrique, Del Carmen, Ignacio, Mohar, Alejandro, Arrieta, Oscar
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067932/
https://ncbi.nlm.nih.gov/pubmed/29490940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados